Divergent adaptive immune responses define two types of long COVID
Authors:
Open Access
- 20 July 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1221961
Abstract
Background: The role of adaptive immune responses in long COVID remains poorly understood, with contrasting hypotheses suggesting either an insufficient antiviral response or an excessive immune response associated with inflammatory damage. To address this issue, we set to characterize humoral and CD4+ T cell responses in long COVID patients prior to SARS-CoV-2 vaccination.Methods: Long COVID patients who were seropositive (LC+, n=28) or seronegative (LC-, n=23) by spike ELISA assay were recruited based on (i) an initial SARS-CoV-2 infection documented by PCR or the conjunction of three major signs of COVID-19 and (ii) the persistence or resurgence of at least 3 symptoms for over 3 months. They were compared to COVID patients with resolved symptoms (RE, n=29) and uninfected control individuals (HD, n=29).Results: The spectrum of persistent symptoms proved similar in both long COVID groups, with a trend for a higher number of symptoms in the seronegative group (median=6 vs 4.5; P=0.01). The use a highly sensitive S-flow assay enabled the detection of low levels of SARS-CoV-2 spike-specific IgG in 22.7% of ELISA-seronegative long COVID (LC-) patients. In contrast, spike-specific IgG levels were uniformly high in the LC+ and RE groups. Multiplexed antibody analyses to 30 different viral antigens showed that LC- patients had defective antibody responses to all SARS-CoV-2 proteins tested but had in most cases preserved responses to other viruses. A sensitive primary T cell line assay revealed low but detectable SARS-CoV-2-specific CD4 responses in 39.1% of LC- patients, while response frequencies were high in the LC+ and RE groups. Correlation analyses showed overall strong associations between humoral and cellular responses, with exceptions in the LC- group.Conclusions: These findings provide evidence for two major types of antiviral immune responses in long COVID. Seropositive patients showed coordinated cellular and humoral responses at least as high as those of recovered patients. In contrast, ELISA-seronegative long COVID patients showed overall low antiviral responses, with detectable specific CD4+ T cells and/or antibodies in close to half of patients (52.2%). These divergent findings in patients sharing a comparable spectrum of persistent symptoms raise the possibility of multiple etiologies in long COVID.Keywords
Funding Information
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales
This publication has 77 references indexed in Scilit:
- Autonomic dysfunction in ‘long COVID’: rationale, physiology and management strategiesClinical Medicine, 2021
- Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19Nature Neuroscience, 2020
- Residual SARS-CoV-2 viral antigens detected in gastrointestinal and hepatic tissues from two recovered COVID-19 patientsmedRxiv, 2020
- Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease SeverityCell, 2020
- A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populationsScience Translational Medicine, 2020
- Persistent Symptoms in Patients After Acute COVID-19JAMA, 2020
- SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controlsNature, 2020
- Olfactory transmucosal SARS-CoV-2 invasion as port of Central Nervous System entry in COVID-19 patientsbioRxiv, 2020
- Viral infections in allergy and immunology: How allergic inflammation influences viral infections and illnessJournal of Allergy and Clinical Immunology, 2017
- Virus infection, antiviral immunity, and autoimmunityImmunological Reviews, 2013